Diclofenac, a phenyl acetic acid NSAID, is anti-inflammatory, analgesic, and antipyretic. Diclofenac inhibits COX-2 more than COX-1, unlike most NSAIDs. Similar to other nonsteroidal antiinflammatory drugs (NSAIDs), diclofenac has serious gastrointestinal, cardiovascular, and renal adverse effects. Since its introduction in 1973, numerous improvements have been made to the efficacy, tolerability, and patient convenience of diclofenac-containing medications. The goal of developing delayed- and extended-release diclofenac sodium was to make the drug safer and make it so that patients with chronic pain only needed to take it once daily. The newer diclofenac potassium salt medications worked and were absorbed more quickly. Immediate-release pills, soft gel capsules, and oral solution powder all include diclofenac potassium. Localized pain and inflammation were alleviated whereas systemic absorption of diclofenac was decreased. Submicron diclofenac free acid particles and a patented excipient mix make up SoluMatrix diclofenac, which gives analgesia at lower doses with less systemic absorption. The pharmacokinetics of diclofenac have been modified by pharmaceutical research to produce new medications with improved clinical efficacy, as demonstrated in this article.

Drug delivery, diclofenac sodium, management, inflammation